Gamma Knife Markets Research Report 2016 - 2024
Download The Full Brouchre of Report: www.transparencymarketresearch.com/sample/sample.php?flag...
The gamma knife market can be segmented by disease indication and geography. Based on disease indication, the market is classified into cancer, arteriovenous malformation (AVM), trigeminal neuralgia, essential tremor and others (epilepsy, Parkinson’s disease etc.). Cancer holds the dominant share of the gamma knife market by disease indication, and its increasing prevalence is expected to boost the overall market. There are over 100 types of cancer. According to WHO, about 16% of the world population die because of cancer. In 2015, 8.8 million people died of cancer. This is expected to be the prominent driver for the gamma knife market.
Geographically, the gamma knife market is classified into five regions, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America has the leading market share followed by the other developed region, Europe. The U.S. accounts for a major share of the global market. According to the American Cancer Society, in 2016, about 1,685,210 new cancer cases were diagnosed. Advanced technologies, high awareness levels, and high purchasing power in North America influenced the gamma knife technology market expansion significantly. However, the same factor of affordability has restrained the markets in developing regions. Despite this, the gamma knife market in Asia Pacific has shown significant increase in growth rate. Rising population, increase in disposable income, increase in the geriatric population, and increase in awareness levels are some key factors driving the Asia Pacific market. Due to these factors, the Asian market is observing a large number of new entrants compared to developed regions.
Browse Global Strategic Business Report: www.transparencymarketresearch.com/gamma-knife-market.html
Other factors that drive the gamma knife market are increasing prevalence of various types of cancer, increasing preference toward non- and minimally-invasive procedures, high adoption and acceptance in developed markets, high success rate of gamma knife procedure, innovations and developments in technology, and comprehensive health insurance cover for radio surgery procedures. The market is also experiencing certain restraints such as stiff competition among existing players, high cost of the procedure, low equipment availability, and lack of awareness about gamma knife therapy among the rural population in developing and underdeveloped economies.
The major players in the gamma knife market include Elekta, Varian Medical Systems, Huiheng Medical, Inc., Nordion Inc., ET Medical Group, and American Shared Hospital Services.
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gamma Knife Markets Research Report 2016 - 2024 here
News-ID: 500651 • Views: 283
More Releases from Transparency Market Research - Medical Devices
Dermatoscope Market - Global Industry Analysis 2024
Dermatoscopy is a process through which the examination of skin lesions can be determined using an instrument, i.e., dermatoscope. The instrument is used by dermatologists to distinguish benign tumors and malignant (cancerous) lesions, especially in the diagnosis of melanoma. Modern dermatoscope uses the liquid medium and polarized light in order to cancel out the skin surface reflection. The images or videos are digitally processed using a digital epiluminescence dermatoscope. 3Gen
Medical Dynamometer Market - Global Industry Analysis and Forecast 2016 - 2024
Dynamometer is a device used for measuring the torque and brake power which is required to operate a driven machine. Dynamometer is designed to be driven in the form of an absorption or passive dynamometer. The device can be in the form of pinch gauge, which is a handheld medical device used for measuring patients’ hand strength and trauma and for determining ongoing therapy and treatment process. It is utilized
Radiation Monitoring and Dosimeter Badges Market - Global Industry Analysis 2016 …
Radiation monitoring is a process that measures the radiation dose or number of radioactive particles reaching a particular surface or area. The radiation monitor device calculates the quantity of radiation present in a given space or received by an individual. The monitors are sensitive and possess properties such as speed counting, spatial resolution, and energy resolution. Radiation monitoring instruments or radiation monitors are used for both individual monitoring and area
Clinical Trial Imaging Market - Analysis and future growth opportunities by 2024
Medical imaging plays a prominent role in clinical trials as it can help in providing answers to the critical challenges that occur in drug development process. It takes about 15 years for a drug to move from a laboratory set-up to FDA approval. The chances of a compound getting regulatory approval are minimal as out of 6 to 11,000 compounds that are evaluated in the pre-clinical stage, only 5 are